1. Medtech Insight
  2. >>Business

Abbott And Coroventis Partner To Address Often-Overlooked Microvascular Dysfunction

 
• By Reed Miller

Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.

Young woman having heart ache.
• Source: shutterstock.com

Abbott and Coroventis are partnering to improve the diagnosis of disease in the heart’s smallest arteries.

Angina is caused by inadequate blood flow (ischemia) in the myocardium, the heart’s muscle. The diagnosis and treatment of angina has traditionally focused on disease in the three major epicardial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.